ASTH vs AGL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ASTH · Astrana Health$34.50 ▼ 11.56%
AGL · Agilon Health$113.39 ▼ 0.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ASTH +53.8%
- AGL +588.3%
Head to head
| Metric | ASTH | AGL |
|---|---|---|
| Price | $34.50 | $113.39 |
| Change today | ▼ 11.56% | ▼ 0.33% |
| Market cap | $1.70B | $1.90B |
| Return, 3 months | -7.9% | +17.2% |
| Return, year to date | +39.1% | +558.3% |
| Return, 1 year | +35.1% | +580.0% |
| P/E (TTM) | 31.9 | – |
| P/B | 2.0 | 6.8 |
| P/E percentile vs own 5y | 73rd | 64th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +48.5% | +7.2% |
| Net profit growth (YoY) | +80.6% | +117.2% |
| Gross margin | 10.5% | 0.2% |
| Operating margin | 2.6% | -4.6% |
| Net margin | 1.1% | -3.9% |
| Return on equity | 5.1% | -73.0% |
| Analyst target vs. price | +51.9% | +3.7% |
| Analyst buy share | 88% | 25% |
| RSI (14) | 40 | 77 |
| 30-day volatility | 53.8% | 64.1% |
| Max drawdown, 1 year | -46.4% | -69.0% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AGL is the largest of the group by market value.
- AGL has returned the most over the past year.
- ASTH is growing revenue fastest.
- ASTH keeps the most profit per dollar of sales.
- ASTH has been the calmest stock over the last 30 days.